196 related articles for article (PubMed ID: 23722543)
1. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment.
Le Mercier I; Poujol D; Sanlaville A; Sisirak V; Gobert M; Durand I; Dubois B; Treilleux I; Marvel J; Vlach J; Blay JY; Bendriss-Vermare N; Caux C; Puisieux I; Goutagny N
Cancer Res; 2013 Aug; 73(15):4629-40. PubMed ID: 23722543
[TBL] [Abstract][Full Text] [Related]
2. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.
Sisirak V; Faget J; Gobert M; Goutagny N; Vey N; Treilleux I; Renaudineau S; Poyet G; Labidi-Galy SI; Goddard-Leon S; Durand I; Le Mercier I; Bajard A; Bachelot T; Puisieux A; Puisieux I; Blay JY; Ménétrier-Caux C; Caux C; Bendriss-Vermare N
Cancer Res; 2012 Oct; 72(20):5188-97. PubMed ID: 22836755
[TBL] [Abstract][Full Text] [Related]
3. Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs.
Hackl D; Loschko J; Sparwasser T; Reindl W; Krug AB
Eur J Immunol; 2011 May; 41(5):1334-43. PubMed ID: 21469103
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.
Sisirak V; Vey N; Goutagny N; Renaudineau S; Malfroy M; Thys S; Treilleux I; Labidi-Galy SI; Bachelot T; Dezutter-Dambuyant C; Ménétrier-Caux C; Blay JY; Caux C; Bendriss-Vermare N
Int J Cancer; 2013 Aug; 133(3):771-8. PubMed ID: 23389942
[TBL] [Abstract][Full Text] [Related]
5. Murine thymic plasmacytoid dendritic cells.
Okada T; Lian ZX; Naiki M; Ansari AA; Ikehara S; Gershwin ME
Eur J Immunol; 2003 Apr; 33(4):1012-9. PubMed ID: 12672067
[TBL] [Abstract][Full Text] [Related]
6. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.
Sugiyama T; Hoshino K; Saito M; Yano T; Sasaki I; Yamazaki C; Akira S; Kaisho T
Int Immunol; 2008 Jan; 20(1):1-9. PubMed ID: 17981792
[TBL] [Abstract][Full Text] [Related]
7. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.
Labidi-Galy SI; Sisirak V; Meeus P; Gobert M; Treilleux I; Bajard A; Combes JD; Faget J; Mithieux F; Cassignol A; Tredan O; Durand I; Ménétrier-Caux C; Caux C; Blay JY; Ray-Coquard I; Bendriss-Vermare N
Cancer Res; 2011 Aug; 71(16):5423-34. PubMed ID: 21697280
[TBL] [Abstract][Full Text] [Related]
8. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
Paget C; Mallevaey T; Speak AO; Torres D; Fontaine J; Sheehan KC; Capron M; Ryffel B; Faveeuw C; Leite de Moraes M; Platt F; Trottein F
Immunity; 2007 Oct; 27(4):597-609. PubMed ID: 17950005
[TBL] [Abstract][Full Text] [Related]
9. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells.
Romagnani C; Della Chiesa M; Kohler S; Moewes B; Radbruch A; Moretta L; Moretta A; Thiel A
Eur J Immunol; 2005 Aug; 35(8):2452-8. PubMed ID: 15997468
[TBL] [Abstract][Full Text] [Related]
10. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
Faget J; Bendriss-Vermare N; Gobert M; Durand I; Olive D; Biota C; Bachelot T; Treilleux I; Goddard-Leon S; Lavergne E; Chabaud S; Blay JY; Caux C; Ménétrier-Caux C
Cancer Res; 2012 Dec; 72(23):6130-41. PubMed ID: 23026134
[TBL] [Abstract][Full Text] [Related]
11. Plasmacytoid dendritic cells promote host defense against acute pneumovirus infection via the TLR7-MyD88-dependent signaling pathway.
Davidson S; Kaiko G; Loh Z; Lalwani A; Zhang V; Spann K; Foo SY; Hansbro N; Uematsu S; Akira S; Matthaei KI; Rosenberg HF; Foster PS; Phipps S
J Immunol; 2011 May; 186(10):5938-48. PubMed ID: 21482736
[TBL] [Abstract][Full Text] [Related]
12. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.
Guillerme JB; Boisgerault N; Roulois D; Ménager J; Combredet C; Tangy F; Fonteneau JF; Gregoire M
Clin Cancer Res; 2013 Mar; 19(5):1147-58. PubMed ID: 23339127
[TBL] [Abstract][Full Text] [Related]
13. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
14. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications.
Guiducci C; Coffman RL; Barrat FJ
J Intern Med; 2009 Jan; 265(1):43-57. PubMed ID: 19093959
[TBL] [Abstract][Full Text] [Related]
15. Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand.
Marshall JD; Heeke DS; Gesner ML; Livingston B; Van Nest G
J Leukoc Biol; 2007 Sep; 82(3):497-508. PubMed ID: 17565046
[TBL] [Abstract][Full Text] [Related]
16. IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response.
Núñez NG; Andreani V; Crespo MI; Nocera DA; Breser ML; Morón G; Dejager L; Libert C; Rivero V; Maccioni M
Cancer Res; 2012 Feb; 72(3):592-603. PubMed ID: 22139376
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines.
Edwards AD; Diebold SS; Slack EM; Tomizawa H; Hemmi H; Kaisho T; Akira S; Reis e Sousa C
Eur J Immunol; 2003 Apr; 33(4):827-33. PubMed ID: 12672047
[TBL] [Abstract][Full Text] [Related]
18. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
Wu P; Wu J; Liu S; Han X; Lu J; Shi Y; Wang J; Lu L; Cao X
Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
20. pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG.
Wu J; Li S; Li T; Lv X; Zhang M; Zang G; Qi C; Liu YJ; Xu L; Chen J
J Immunol Res; 2019; 2019():1749803. PubMed ID: 31093508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
